PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)

Launched by FEDERAL UNIVERSITY OF SÃO PAULO · Aug 4, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new approach to help patients with anemia who need coronary artery bypass grafting (CABG), a type of heart surgery. Anemia, which means having low levels of red blood cells, can lead to more complications during and after surgery. The trial is comparing three groups of patients: one group will receive standard care, another group will get blood transfusions, and the last group will be treated with a medication called erythropoietin (EPO) to stimulate the production of red blood cells. The researchers want to see if using EPO can reduce the need for blood transfusions and improve recovery after surgery.

To be eligible for the trial, participants must be scheduled for elective CABG surgery and be between the ages of 65 and 80. However, certain conditions might exclude someone from participating, such as having severe kidney disease, other major heart issues, or certain blood levels. If you join the study, you will be monitored closely for things like how long you stay in the hospital, any complications, and your overall recovery. This research is important because it aims to find safer ways to manage anemia in heart surgery patients, potentially leading to better outcomes and fewer complications.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Eletive surgery;
• • Only CABG as procedure;
• • Off pump CABG candidate.
• Exclusion Criteria:
• • Age \> 80 years;
• • Chronic dialytic kidney disease;
• • Chronic rheumatologic disease;
• • Men with Hb levels \> 13 g/dl and \< 8g/dl;
• • Women with Hb levels \> 12 g/dl and \< 8g/dl;
• • Presence of another heart disease requiring surgical intervention;
• • Presence of hepatic insufficiency;
• • Presence of any implantable electronic cardiac device in any cardiac chambers;
• • Pregnancy;
• • Diagnosis of malignant neoplasia;
• • Thrombophilias;
• • Need for Erythropoietin treatment due to any other disease.
• • Recent ischemic event (\< 3 months).
• • Ejection fraction \<30%.